Clinical Trials Logo
  1. Home
  2. Hepatitis
  3. NCT02342821
  4. Details
NCT02342821 Clinical Trial

Empowering Immigrants in the Greater Boston Area to Connect to HBV Care

Hepatitis Clinical Trial

Official title:
Empowering Immigrants in the Greater Boston Area to Connect to HBV Care

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT02342821
Other study ID # IN-US-174-1254
Secondary ID
Status Active, not recruiting
Phase N/A
First received January 16, 2015
Last updated March 26, 2017
Start date February 2015
Est. completion date June 2017

Study information
Verified date March 2017
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This Study will attempt to provide information / linkage to HBV care for persons at risk in the Greater Boston area.

Description:

Specific Aims

1. Provide HBV education at community sites where immigrants at risk for HBV could be informed of the risks related to HBV, in a culturally and linguistically sensitive manner.

1. Chelsea, Charlestown, and Revere MGH Community Health Centers: posters, pamphlets, and telephone line to provide HBV education

2. Senegalese Community Center: community meeting, posters, and pamphlets

3. African Students' Association, Suffolk University: community meeting, posters, and pamphlets

4. Revere Cambodian Community Centers: community meeting, posters, and pamphlets

2. Provide at-risk persons with the tools to develop an HBV diagnosis plan with his / her provider.

1. Provide counseling on the significance of different testing results prior to testing

2. Connect to testing, and appropriate post-test follow-up appointments

3. Provide an education hub for patients and providers to return to with questions regarding: test interpretation, available treatments for those who test positive, and screening for hepatocellular carcinoma in those who are infected.

1. Provide copy of an easy to understand US HBV treatment algorithm in native languages

2. Provide information related to genotype-specific risks for HCC (increased with GT C).

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 100
Est. completion date June 2017
Est. primary completion date May 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: all persons interested in hearing more information about HBV -

Exclusion Criteria: children

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (2)
Lead Sponsor Collaborator
Massachusetts General Hospital Gilead Sciences

Outcome
Type Measure Description Time frame Safety issue
Primary Improved understanding of HBV by Questionnaire Participants will be provided questionnaires by D. Fusco 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05989958 - The Safety and Tolerability Study of HepaCure in Chinese Subjects With Acute-On-Chronic Liver Failure Phase 1
Not yet recruiting NCT06395129 - Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries
Terminated NCT01443923 - Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV Phase 4
Completed NCT00679692 - Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease N/A
Completed NCT00300209 - Manhattan HIV/Hepatology Brain Bank N/A
Recruiting NCT05563961 - A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers N/A
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT00160407 - Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Phase 4
Recruiting NCT03692897 - An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Completed NCT03509688 - The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial N/A
Recruiting NCT02275195 - Immune Cell Dysfunction in Severe Alcoholic Hepatitis
Completed NCT01740089 - Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C Phase 2/Phase 3
Completed NCT00987337 - Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects Phase 2
Completed NCT00929786 - Anti-tuberculosis (TB) Drug Levels and Hepatotoxicity N/A
Completed NCT00564642 - Investigation of the Effect of N Acetylcysteine Against Anti-Tuberculosis Drugs Induced Liver Toxicity N/A
Completed NCT00080236 - Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation Phase 2
Recruiting NCT05719480 - A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Liver Cancer
Suspended NCT04306939 - Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
Completed NCT03482388 - Crowdsourcing to Promote HBV and HCV Testing in China N/A